9月14日，金斯瑞生物科技盘中下跌3.15%，报31.16港元/股，成交额5301.35万港元。
消息面上，公司此前公告以每股30.50港元的价格配售7712.6万股新股，较前一交易日收市价32.00港元折让约4.7%，净筹资金约23.27亿港元，由花旗及摩根大通担任配售代理，预期交割日期为9月15日或之前。配售完成后，大股东GenScript Corporation持股比例将由36.32%摊薄至35.09%。随着配售交割临近，短期稀释效应及配售价对市价的牵引作用令股价承压。募集资金方面，约70%将用于扩大AIDD平台产能及基础设施，约20%用于相关研发及全球业务拓展，约10%用于一般企业用途。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.